Abstract
The production of viral vaccines in animal cell culture can be accomplished with primary, diploid, or continuous (transformed) cell lines. Each cell line, each virus type, and each vaccine definition requires a specific production and purification process. Media have to be selected as well as the production vessel, production conditions, and type of process. Here, we describe different issues that have to be considered during virus-production processes by discussing the influenza virus production in a microcarrier system in detail as an example. The use of serum-containing as well as serum-free media, but also the use of stirred tank bioreactors or wave bioreactors, is considered.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Kaufmann, S. H. E. (ed.) (2004) Novel Vaccination Strategies. Wiley-VCH, Weinheim.
Huang, D. B., Wu, J. J., and Tyring, S. K. (2004) A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J. Infect. 49, 179–209.
Aunins, J. G. (2000) Viral vaccine production in cell culture, in Encyclopedia of Cell Technology (Stier, R. E., ed.), Wiley & Sons, New York, pp. 1182–1217.
Reichl, U. (2000) ISCOM vaccines—antigen production and downstream processing, in Proc. 4th Int. Congress on Biochemical Engineering, Fraunhofer IRB Verlag, Stuttgart, pp. 314–318.
Genzel, Y., Voges, L., and Reichl, U. (2001) Development of bioprocess concepts on vaccine production: influenza virus as an example, in Animal Cell Technology: From Target to Market (Lindner-Olsson, Chatzissavidou, N., and Lüllau, E., eds.), Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 344–346.
Tree, J. A., Richardson, C., Fooks, A. R., Clegg, J. C., and Looby, D. (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19, 3444–3450.
Robertson, J. S., Cook, P., Attwell, A.-M., and Williams, S. P. (1995) Replicative advantage in tissue culture of egg-adapted influenza virus over tissue culture derived virus: implications for vaccine manufacture. Vaccine 13(16), 1583–1588.
Govorkova, E. A., Kodihalli, S., Alymova, I. V., Fanget, B., and Webster, R. G. (1999) Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev. Biol. Stand. 98, 39–51.
Genzel, Y., Behrendt, I., König, S., Sann, H., and Reichl, U. (2004) Metabolism of MDCK Cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 22(17–18), 2202–2208.
Genzel, Y., Ritter, J. B., König, S., Alt, R., and Reichl, U. (2005) Substitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells. Biotechnol. Progr. 21(1), 58–69.
Genzel, Y., Olmer, R. M., Schafer, B., and Reichl, U. (2006) Wave microcarriers cultivation of MDCK cells for influenza virus production in serum-containing and serum-free media. Vaccine 24(35–36), 6074–6087.
Kistner, O., Barrett, P. N., Mundt, W., Reiter, M., Schober-Bendixen, S., and Dorner, F. (1998) Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16(9/10), 960–968.
Pau, M. G., Ophorst, C., Koldijk, M. H., Schouten, G., Mehtali, M., and Uytdehaag, F. (2001) The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19, 2716–2721.
Bahnemann, H. G. (1990) Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 8(4), 299–303.
Budowsky, E. I. and Zalesskaya, M. A. (1991) Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of beta-propiolactone. Vaccine 9(5), 319–325.
Budowsky, E. I., Friedman, E. A., Zheleznova, N. V., and Noskov, F. S. (1991) Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone. Vaccine 9(6), 398–402.
Mahy, B. W. J. and Kangro, H. O. (eds.) (1996) Virology Methods Manual. Academic Press, London, pp. 41–43.
“The Orange Guide”: Rules and Guidance for Pharmaceutical Manufactures and Distributors (2002), Medicines Control Agency, 6th ed. London, United Kingdom, ISBN 0113225598.
European Pharmacopoeia (EP), Maisonneuve S. A. France, continuously updated.
United States Pharmacopoeia (USP), US Pharmacopeial Convention, Rockville, MD, continuously updated.
Points to consider in the characterization of cell lines used to produce biologicals. (1993) Department of Health and Human Services, Food and Drug Administration, Docket No. 84N-0154.
Guidance on viral safety evaluation of biotechnology products derived from cell lines of human and animal origin. (1998) Department of Health and Human Services, Food and Drug Administration (FDA), Docket No. 96D-0058.
Gregersen, J.-P. (1994) Research and Development of Vaccines and Pharmaceuticals from Biotechnology. VCH, Weinheim, Germany.
Möhler, L., Flockerzi, D., Sann, H., and Reichl, U. (2005) Mathematical model of influenza A virus production in large-scale microcarrier culture. Biotechnol. Bioeng. 90(1), 46–58.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Genzel, Y., Reichl, U. (2007). Vaccine Production. In: Pörtner, R. (eds) Animal Cell Biotechnology. Methods in Biotechnology, vol 24. Humana Press. https://doi.org/10.1007/978-1-59745-399-8_21
Download citation
DOI: https://doi.org/10.1007/978-1-59745-399-8_21
Publisher Name: Humana Press
Print ISBN: 978-1-58829-660-3
Online ISBN: 978-1-59745-399-8
eBook Packages: Springer Protocols